Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.13 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

May 09, 2023

From Verve Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023 ↗

April 13, 2023

Via Benzinga

Verve Therapeutics's Return On Capital Employed Insights ↗

March 08, 2023

Via Benzinga

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global ↗

April 06, 2023

Via Benzinga

Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

March 27, 2023

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

March 03, 2023

From Verve Therapeutics

Via GlobeNewswire

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

March 02, 2023

From Verve Therapeutics

Via GlobeNewswire

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

3 Deeply Undervalued Stocks That Could Double Your Money ↗

February 15, 2023

These cutting-edge biotech stocks hold tremendous upside potential.

Via The Motley Fool

Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia

February 14, 2023

From Verve Therapeutics

Via GlobeNewswire

Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics ↗

February 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away' ↗

January 04, 2023

Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.

Via Benzinga

Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Verve Therapeutics

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

December 23, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗

December 22, 2022

Crispr and Vertex are working toward the first submissions for a CRISPR-based product.

Via Investor's Business Daily

Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside' ↗

December 20, 2022

Via Benzinga

Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session ↗

December 15, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

December 15, 2022

The growth-focused money manager is making moves.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗

December 15, 2022

Via Benzinga

Cathie Wood Adds $7M Of This Clinical-Stage Biotech, Trims Stake In CVS-Target Signify Health ↗

December 07, 2022

Cathie Wood-led ARK Investment Management bought over 330,000 shares of clinical-stage biotechnology company Verve Therapeutics Inc (NASDAQ: VERV) at an estimated valuation of over $6.9 million, based...

Via Benzinga

Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session ↗

December 05, 2022

Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.

Via Benzinga

Gold Down 1%; China Pharma Shares Spike Higher ↗

December 05, 2022

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 200 points on Monday.

Via Benzinga

VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗

December 05, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Start Week On Lower Note; Dow Tumbles 250 Points ↗

December 05, 2022

U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday.

Via Benzinga

Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns ↗

December 05, 2022

The company has a long list of issues to address to satisfy the FDA's worries.

Via Investor's Business Daily

Looking Into Verve Therapeutics's Recent Short Interest ↗

November 23, 2022

Verve Therapeutics's (NASDAQ:VERV) short percent of float has fallen 10.98% since its last report. The company recently reported that it has 10.05 million shares sold short, which is 29.91% of all...

Via Benzinga

Verve Therapeutics to Participate in Upcoming Investor Conferences

November 11, 2022

From Verve Therapeutics

Via GlobeNewswire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.